Fluicell AB (publ) (STO:FLUI)

Market Cap	38.88M +132.0%
Revenue (ttm)	20.06M +133.0%
Net Income	-2.35M
EPS	n/a
Shares Out	1.37M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,795
Average Volume	26,858
Open	28.20
Previous Close	28.30
Day's Range	27.50 - 30.90
52-Week Range	7.45 - 43.10
Beta	1.47
RSI	62.59
Earnings Date	Aug 21, 2026

About Fluicell AB

Fluicell AB (publ), a life science company, develops and provides clay instruments for 3D bioprinting and cell analysis and flow control on single-cell level in Sweden. The company offers BIOPEN, a powerful tool for high precision cell biology that uses open volume microfluidics; Biozone 6 that generate dose-response curves or study the effects of multiple drug compounds; and Dynaflow Resolve system, an ion channel screening platform, which allows to record various ion channel current in patch clamp recording configuration. It also provides Bio...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 11
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: FLUI

Financial Performance

In 2025, Fluicell AB's revenue was 15.22 million, an increase of 184.54% compared to the previous year's 5.35 million. Losses were -8.33 million, -46.28% less than in 2024.